Sensus Healthcare (SRTS) Stock

The latest trading day saw Sensus Healthcare, Inc. (SRTS) settling at $7.21, representing a -1.77% change from its previous close.

Sensus Healthcare (SRTS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

In the latest trading session, Sensus Healthcare, Inc. (SRTS) closed at $7.10, marking a -1.53% move from the previous day.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

The average of price targets set by Wall Street analysts indicates a potential upside of 36% in Sensus Healthcare (SRTS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The mean of analysts' price targets for Sensus Healthcare (SRTS) points to a 39.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Sensus Healthcare (SRTS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer's request. The agreement with the new customer remains in effect.

Sensus Healthcare's Q3 results exceeded expectations with 127% YoY revenue growth and EPS of $0.07, showcasing strong demand recovery and effective management strategies. The Fair Deal Agreement and new FDA contracts, including a major deal with Platinum Dermatology, promise recurring revenue and reduced client concentration risk. Despite impressive financial performance, the stock saw minimal movement, presenting a potential 150% upside over the next five years under my assumptions.